Late cutaneous form of porphyria cutanea tarda in a 26-year-old man: a clinical case report

Jenish Lakhabhai  Vekariya; Alexandra L. Potapchik; Yana Igorevna Kalninya; Ketan Nandkishor Patil

doi:10.18203/2349-3933.ijam20261886

Authors

Jenish Lakhabhai Vekariya Department of Infectious Diseases, Grodno State Medical University, Grodno, Belarus
Alexandra L. Potapchik Department of Infectious Diseases, Grodno State Medical University, Grodno, Belarus
Yana Igorevna Kalninya Department of Infectious Diseases, Grodno State Medical University, Grodno, Belarus
Ketan Nandkishor Patil Department of Infectious Diseases, Grodno State Medical University, Grodno, Belarus

DOI:

https://doi.org/10.18203/2349-3933.ijam20261886

Keywords:

Porphyria cutanea tarda, Uroporphyrinogen decarboxylase, Familial PCT, HCV, Phlebotomy

Abstract

Porphyria cutanea tarda (PCT) is a rare form of enzymatic disorder of heme-biosynthesis pathway. Due to a defect of enzyme uroporphyrinogen decarboxylase (UROD) this disease occurs. Porphyria cutanea tarda can be sporadic and can be familial. Here, we are presenting a late cutaneous form of porphyria cutanea tarda in a 26-year-old male patient without any known triggers. The patient was diagnosed by genetic and laboratory testing and showed typical appearance of PCT. All the details of PCT from presentation of symptoms, complications, involvement of organs and diagnosis is discussed in this article. Furthermore, this article provides thorough discussion about PCT.

Metrics

Metrics Loading ...

References

Leaf RK, Dickey AK. Porphyria cutanea tarda: a unique iron-related disorder. Hematology. 2024;2024(1):450-6. DOI: https://doi.org/10.1182/hematology.2024000664

Aarsand AK, Boman H, Sandberg S. Familial and Sporadic Porphyria Cutanea Tarda: Characterization and Diagnostic Strategies. Clin Chem. 2009;55(4):795-803. DOI: https://doi.org/10.1373/clinchem.2008.117432

Rossmann‐Ringdahl I, Olsson R. Porphyria Cutanea Tarda in a Swedish Population: Risk Factors and Complications. Acta Derm Venereol. 2005;85(4):337-41. DOI: https://doi.org/10.1080/00015550510033688

Cabezas Arteaga JE, Vieira FMJ, Silva Dos Reis VM. Experience in management of porphyria cutanea tarda in a tertiary referral Brazilian hospital from 2002 to 2017. Int J Dermatol. 2019;58(8):925-32. DOI: https://doi.org/10.1111/ijd.14398

Chaiyabutr C, Dawe R, Ibbotson SH, Clarke T, McGuire VA. Porphyria cutanea tarda in Scotland: underlying associations and treatment approaches. Int J Dermatol. 2024;63(12):1707-12. DOI: https://doi.org/10.1111/ijd.17205

Usta Atmaca H, Akbas F. Porphyria cutanea tarda: a case report. J Med Case Reports. 2019;13(1):17. DOI: https://doi.org/10.1186/s13256-018-1956-9

Muñoz-Santos C, Guilabert A, Moreno N, de Salamanca RE, Badenas C, Herrera E, et al. Familial and sporadic porphyria cutanea tarda: clinical and biochemical features and risk factors in 152 patients. Medicine (Baltimore). 2010;89(2):69-74. DOI: https://doi.org/10.1097/MD.0b013e3181d50928

Bulaj ZJ, Phillips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood. 2000;95(5):1565-71. DOI: https://doi.org/10.1182/blood.V95.5.1565.005k42_1565_1571

Awad A, Nirenberg A, Sinclair R. Case Report: Treatment of porphyria cutanea tarda with low dose hydroxychloroquine. F1000Research. 2022;11:945. DOI: https://doi.org/10.12688/f1000research.124022.1

Jalil S, Grady JJ, Lee C, Anderson KE. Associations Among Behavior-Related Susceptibility Factors in Porphyria Cutanea Tarda. Clin Gastroenterol Hepatol. 2010;8(3):297-302. DOI: https://doi.org/10.1016/j.cgh.2009.11.017

Frausto De La Cruz ER, Guzmán-Ramos JA, Hernández-Villanueva MF, Jiménez-López MA, Lazalde B. Genetic and clinical approach in acute intermittent porphyria and porphyria cutanea tarda. GSC Adv Res Rev. 2024;21(2):350-8. DOI: https://doi.org/10.30574/gscarr.2024.21.2.0443

Soufleris S, Moore M, Phillips JD, Ranganathan S, Magsino K. Novel UROD mutation for porphyria cutanea tarda, type 2: a case report. AME Case Rep. 2024;8:67. DOI: https://doi.org/10.21037/acr-23-66

Krivosheev AB, Kondratova MA, Gurazheva AA, Maksimov VN. HFE hemochromatosis gene polymorphism and porphyria cutanea tarda. Exp Clin Gastroenterol. 2023;(4):28-36. DOI: https://doi.org/10.31146/1682-8658-ecg-212-4-28-36

Rossmann-Ringdahl I, Olsson R. Porphyria Cutanea Tarda: Effects and Risk Factors for Hepatotoxicity from High-dose Chloroquine Treatment. Acta Derm Venereol. 2007;87(5):401-5. DOI: https://doi.org/10.2340/00015555-0260

Pavlidou DC, Van Winckel G, Tran C. When Simple Phlebotomy Is the Cure: Porphyria Cutanea Tarda. J Gen Intern Med. 2022;37(13):3489-90. DOI: https://doi.org/10.1007/s11606-022-07740-w

Salameh H, Sarairah H, Rizwan M, Kuo YF, Anderson KE, Singal AK. Relapse of porphyria cutanea tarda after treatment with phlebotomy or 4-aminoquinoline antimalarials: a meta-analysis. Br J Dermatol. 2018;179(6):1351-7. DOI: https://doi.org/10.1111/bjd.16741

Lederhandler M, Chen L, Meehan SA, Brinster NK, Neimann AL. A case of porphyria cutanea tarda in the setting of hepatitis C infection and tobacco usage. Dermatol Online J. 2019;25(12):13030/qt0d46727. DOI: https://doi.org/10.5070/D32512046727

Andersen J, Gjengedal E, Sandberg S, Råheim M. A skin disease, a blood disease or something in between? An exploratory focus group study of patients’ experiences with porphyria cutanea tarda. Br J Dermatol. 2015;172(1):223-9. DOI: https://doi.org/10.1111/bjd.13198

Prasad S, Vidhata V, Prasad S. Sight-threatening progressive corneo-scleral involvement in porphyria cutanea tarda. BMJ Case Rep. 2021;14(10):e245160. DOI: https://doi.org/10.1136/bcr-2021-245160